Compare NSSC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | NVCR |
|---|---|---|
| Founded | 1969 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | NSSC | NVCR |
|---|---|---|
| Price | $42.65 | $12.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $47.50 | $28.42 |
| AVG Volume (30 Days) | 386.8K | ★ 1.8M |
| Earning Date | 02-02-2026 | 10-30-2025 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | $186,786,000.00 | ★ $642,269,000.00 |
| Revenue This Year | $13.13 | $9.75 |
| Revenue Next Year | $9.55 | $5.62 |
| P/E Ratio | $34.50 | ★ N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $19.00 | $10.70 |
| 52 Week High | $48.12 | $34.13 |
| Indicator | NSSC | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 52.61 |
| Support Level | $40.99 | $10.79 |
| Resistance Level | $43.21 | $13.94 |
| Average True Range (ATR) | 1.50 | 0.63 |
| MACD | 0.29 | 0.12 |
| Stochastic Oscillator | 88.20 | 60.63 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.